1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Pattern characteristics and analysis^{^a}
Subpatterns P Value Pattern 1 Overall Pattern 2 P Value
1.1 1.2 1.3
Median age at onset (mo) 45.4 66 80.5 .5 55.5 16 .004
Symptoms
 Seizures 11/21 (52%) 4/5 (80%) 4/6 (67%) .5 19/32 (59%) 9/25 (36%) .08
 Encephalopathy 11/21 (52%) 1/5 (20%) 4/6 (67%) .3 16/32 (50%) 6/25 (24%) .04
 Gait ataxia 5/21 (24%) 3/5 (60%) 3/6 (50%) .08 12/32 (34%) 0 .001
 Limb weakness 6/21 (29%) 1/5 (20%) 1/6 (17%) .8 8/32 (25%) 1/25 (4%) .03
 Dysarthria 0 2/5 (40%) 1/6 (17%) .01 3/32 (9%) 1/25 (4%) .4
 Diplopia 01/21 (5%) 2/5 (40%) 2/6 (33%) .06 5/32 (16%) 0 .03
Abnormal CSF 18/20 (90%) 4/5 (80%) 5/5 (100%) .6 27/30 (90%) 15/20(75%) .2
Proteinosis 13 (65%) 4 (80%) 4 (80%) .5 21 (70%) 11 (55%) .3
Pleocytosis 10 (50%) 4 (80%) 5 (100%) .08 19 (63%) 6 (30%) .04
Pooled mutation group 4/6 (67%) 2/3 (67%) 3/3 (100%) .32 9/12 (75%) 13/13 (100%) .09
 Mortality 9/20 (45%) 3/5 (60%) 2/6 (33%) .3 14/31 (45%) 5/24 (21%) .06
Deficit-free at follow-up 8/20 (40%) 1/5 (20%) 1/6 (17%) .1 10/31 (32%) 13/25(52%) .06
↵a Data collected are both continuous and categorical, and the analysis method used has been referred to under statistical analysis heading.